| Dr Lora Dean Sztendera, MD | |
|
407 E 1st St, Campbellsville, KY 42718-1387 | |
| (270) 465-4841 | |
| (270) 465-0120 |
| Full Name | Dr Lora Dean Sztendera |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 36 Years |
| Location | 407 E 1st St, Campbellsville, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114069481 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 26865 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health | Columbia, KY | Home health agency |
| Lifeline Health Care Of Pulaski | Somerset, KY | Home health agency |
| Taylor Regional Hospital | Campbellsville, KY | Hospital |
| Entity Name | Taylor County Family Practice Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013035419 PECOS PAC ID: 4486670627 Enrollment ID: O20051018000425 |
News Archive
As millions of Americans prepare to enjoy the great outdoors Memorial Day weekend, the National Council on Skin Cancer Prevention reminds everyone to practice sun-safe behaviors – pack those wide-brimmed hats in the suitcase. The incidence of melanoma (the most fatal of skin cancers) continues to rise significantly, at a rate faster than any of the seven most common cancers.
Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.
"House Democrats released the outline of their health care reform bill Friday - a proposal that would create a public insurance option, expand Medicaid, and require employers to provide coverage or pay a tax," Politico reports. "The outline did not include details on how Democrats would pay for the plan."
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lora Dean Sztendera, MD 407 E 1st St, Campbellsville, KY 42718-1387 Ph: (270) 465-4841 | Dr Lora Dean Sztendera, MD 407 E 1st St, Campbellsville, KY 42718-1387 Ph: (270) 465-4841 |
News Archive
As millions of Americans prepare to enjoy the great outdoors Memorial Day weekend, the National Council on Skin Cancer Prevention reminds everyone to practice sun-safe behaviors – pack those wide-brimmed hats in the suitcase. The incidence of melanoma (the most fatal of skin cancers) continues to rise significantly, at a rate faster than any of the seven most common cancers.
Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.
"House Democrats released the outline of their health care reform bill Friday - a proposal that would create a public insurance option, expand Medicaid, and require employers to provide coverage or pay a tax," Politico reports. "The outline did not include details on how Democrats would pay for the plan."
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
› Verified 1 days ago
Brandi Lauren Johns, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Winston Way Ste C&d, Campbellsville, KY 42718 Phone: 270-465-9400 Fax: 270-469-4893 | |
Mrs. Kellee D. Frogge, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 105 Greenbriar Dr, Suite B, Campbellsville, KY 42718 Phone: 270-465-0191 Fax: 270-465-0463 | |
William Griffin Tucker, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 219 Meader Street, Village J, Campbellsville, KY 42718 Phone: 270-789-6112 Fax: 270-789-6094 | |
Kendra Denise Sublett, MSN, APRN, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 125 Kingswood Dr, Campbellsville, KY 42718 Phone: 270-789-1112 Fax: 270-789-6176 | |
Summer Raye Tucker, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 410 Hotchkiss St, Campbellsville, KY 42718 Phone: 270-465-0191 Fax: 270-465-0463 | |
Bobby Joe Brooks, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 127 Kingswood Dr, Campbellsville, KY 42718 Phone: 270-789-3410 Fax: 270-465-2449 |